Hospital News and Research

RSS

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.

12 May 2011

Being mildly overweight benefits ALS patients

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts General Hospital researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

12 May 2011

State roundup: Daniels signs Ind. law to ban Planned Parenthood funding

Indiana Gov. Mitch Daniels, a Republican considering a run for president, signed legislation Tuesday to bar Planned Parenthood from receiving federal funding in his state, a move widely seen as a bid to woo influential social conservatives. Planned Parenthood of Indiana and the American Civil Liberties Union went to court to try to block the measure from taking effect.

12 May 2011

Accretive Health first quarter net services revenue increases 30% to $163.7 million

Accretive Health, Inc., a leading provider of comprehensive end-to-end healthcare revenue cycle management services and population health management services infrastructure, today announced financial results for the quarter ended March 31, 2011.

11 May 2011

SunLink Health Systems third quarter net earnings increases to $2,683,000

SunLink Health Systems, Inc. today announced earnings from continuing operations for its fiscal quarter ended March 31, 2011 of $2,515,000, or $0.31 per fully diluted share, compared to earnings from continuing operations of $469,000, or $0.06 per fully diluted share, for the comparable quarter ended March 31, 2010.

11 May 2011

American Medical Alert first quarter net income increases 18% to $1,046,378

American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter ended March 31, 2011, the

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

New poll: Ontarians support more public investment in home and community support services

A new poll shows Ontarians support more public investment in home and community support services with six in ten (59%) agreeing new funding is better designated to these preventative care services rather than facilities and full-time nursing care.

11 May 2011

TSO3 first quarter revenue decreases to $136,628

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, posted revenues of $136,628 for the first quarter of 2011 ending March 31, for the sale of supplies, accessories and service contracts for the first generation product.

11 May 2011

Heart docs dismiss bias claims stemming from industry support of meeting

Doctors said the heart society meeting was an important opportunity to learn about new research in their field and see new products on the market. Unlike in many other areas of medicine, they said, electrophysiologists work hand-in-hand with device company representatives to program implantable defibrillators and diagnose problems.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

USA Today: Uninsured hospitalizations result in a hefty unpaid tab

Uninsured Americans — including those with incomes well above the poverty line — leave hospitals with unpaid tabs of up to $49 billion a year, according to a government study released today. On average, uninsured families pay only about 12 percent of their hospital bills in full.

11 May 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

11 May 2011

Reducing hearing aid cost does not improve device purchase

Lowering the cost of hearing aids isn't enough to motivate adults with mild hearing loss to purchase a device at a younger age or before their hearing worsens, according to researchers at Henry Ford Hospital.

11 May 2011

Study stresses importance of rapid intervention to prevent Self-Embedding Behavior in adolescents

While the disturbing act of self-injury is nothing new to adolescents, researchers and physicians at Nationwide Children's Hospital have identified a more severe type of behavior that is raising some concern among medical professionals.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Scientists to develop 'eTraining' system for doctors and healthcare providers

Many people use fitness studios to get back into shape after an injury. Fraunhofer researchers are now developing a system that will provide doctors with data on the exercises people do on the various machines. This should help them plan better training programs.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011